Glenmark, Cosmo get MHRA nod for acne treatment medication

Glenmark Pharmaceuticals and Cosmo Pharmaceuticals have received MHRA approval to market Winlevi, a topical acne treatment for patients aged 12 and older in the UK. Glenmark licensed the product from Cosmo for distribution in Europe and South Africa, aiming to improve the quality of life for those suffering from acne, which affects a significant portion of the global population.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/fBYa3Gz
via IFTTT